Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases

Joshua D. Udoetuk, Yang Dai, Gui Shuang Ying, Ebenezer Daniel, Sapna Gangaputra, James (Jim) Rosenbaum, Eric Suhler, Jennifer E. Thorne, C. Stephen Foster, Douglas A. Jabs, Grace A. Levy-Clarke, Robert B. Nussenblatt, John H. Kempen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To identify the incidence and risk factors for corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Design: Retrospective cohort study. Participants: Patients with ocular inflammation followed at 5 United States tertiary centers that initially were neither diabetic nor taking hypoglycemic medications. Methods: Eligible patients who used oral corticosteroids during follow-up were identified and followed longitudinally for initiation of hypoglycemic medication over 1 year after beginning corticosteroids. The remaining eligible patients were followed for 1 year after their initial visit. Survival analysis was used to calculate the risk of hyperglycemia requiring medical therapy and to identify potential risk factors. Main Outcome Measures: Initiation of hypoglycemic medications. Results: Among 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21%) initiated hypoglycemic therapy compared with 5 of 2666 patients (0.19%) not treated with oral corticosteroids (relative risk [RR], 4.39; 95% confidence interval [CI], 1.68-11.5). The RR tended to be higher in association with higher initial doses (for initial doses

Original languageEnglish (US)
Pages (from-to)1569-1574
Number of pages6
JournalOphthalmology
Volume119
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Eye Diseases
Hyperglycemia
Adrenal Cortex Hormones
Hypoglycemic Agents
Therapeutics
Survival Analysis
Cohort Studies
Retrospective Studies
Outcome Assessment (Health Care)
Confidence Intervals
Inflammation
Incidence

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. / Udoetuk, Joshua D.; Dai, Yang; Ying, Gui Shuang; Daniel, Ebenezer; Gangaputra, Sapna; Rosenbaum, James (Jim); Suhler, Eric; Thorne, Jennifer E.; Foster, C. Stephen; Jabs, Douglas A.; Levy-Clarke, Grace A.; Nussenblatt, Robert B.; Kempen, John H.

In: Ophthalmology, Vol. 119, No. 8, 08.2012, p. 1569-1574.

Research output: Contribution to journalArticle

Udoetuk, JD, Dai, Y, Ying, GS, Daniel, E, Gangaputra, S, Rosenbaum, JJ, Suhler, E, Thorne, JE, Foster, CS, Jabs, DA, Levy-Clarke, GA, Nussenblatt, RB & Kempen, JH 2012, 'Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases', Ophthalmology, vol. 119, no. 8, pp. 1569-1574. https://doi.org/10.1016/j.ophtha.2012.01.043
Udoetuk, Joshua D. ; Dai, Yang ; Ying, Gui Shuang ; Daniel, Ebenezer ; Gangaputra, Sapna ; Rosenbaum, James (Jim) ; Suhler, Eric ; Thorne, Jennifer E. ; Foster, C. Stephen ; Jabs, Douglas A. ; Levy-Clarke, Grace A. ; Nussenblatt, Robert B. ; Kempen, John H. / Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. In: Ophthalmology. 2012 ; Vol. 119, No. 8. pp. 1569-1574.
@article{030ed3097b054e5787965d400ff0aec4,
title = "Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases",
abstract = "Objective: To identify the incidence and risk factors for corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Design: Retrospective cohort study. Participants: Patients with ocular inflammation followed at 5 United States tertiary centers that initially were neither diabetic nor taking hypoglycemic medications. Methods: Eligible patients who used oral corticosteroids during follow-up were identified and followed longitudinally for initiation of hypoglycemic medication over 1 year after beginning corticosteroids. The remaining eligible patients were followed for 1 year after their initial visit. Survival analysis was used to calculate the risk of hyperglycemia requiring medical therapy and to identify potential risk factors. Main Outcome Measures: Initiation of hypoglycemic medications. Results: Among 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21{\%}) initiated hypoglycemic therapy compared with 5 of 2666 patients (0.19{\%}) not treated with oral corticosteroids (relative risk [RR], 4.39; 95{\%} confidence interval [CI], 1.68-11.5). The RR tended to be higher in association with higher initial doses (for initial doses",
author = "Udoetuk, {Joshua D.} and Yang Dai and Ying, {Gui Shuang} and Ebenezer Daniel and Sapna Gangaputra and Rosenbaum, {James (Jim)} and Eric Suhler and Thorne, {Jennifer E.} and Foster, {C. Stephen} and Jabs, {Douglas A.} and Levy-Clarke, {Grace A.} and Nussenblatt, {Robert B.} and Kempen, {John H.}",
year = "2012",
month = "8",
doi = "10.1016/j.ophtha.2012.01.043",
language = "English (US)",
volume = "119",
pages = "1569--1574",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases

AU - Udoetuk, Joshua D.

AU - Dai, Yang

AU - Ying, Gui Shuang

AU - Daniel, Ebenezer

AU - Gangaputra, Sapna

AU - Rosenbaum, James (Jim)

AU - Suhler, Eric

AU - Thorne, Jennifer E.

AU - Foster, C. Stephen

AU - Jabs, Douglas A.

AU - Levy-Clarke, Grace A.

AU - Nussenblatt, Robert B.

AU - Kempen, John H.

PY - 2012/8

Y1 - 2012/8

N2 - Objective: To identify the incidence and risk factors for corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Design: Retrospective cohort study. Participants: Patients with ocular inflammation followed at 5 United States tertiary centers that initially were neither diabetic nor taking hypoglycemic medications. Methods: Eligible patients who used oral corticosteroids during follow-up were identified and followed longitudinally for initiation of hypoglycemic medication over 1 year after beginning corticosteroids. The remaining eligible patients were followed for 1 year after their initial visit. Survival analysis was used to calculate the risk of hyperglycemia requiring medical therapy and to identify potential risk factors. Main Outcome Measures: Initiation of hypoglycemic medications. Results: Among 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21%) initiated hypoglycemic therapy compared with 5 of 2666 patients (0.19%) not treated with oral corticosteroids (relative risk [RR], 4.39; 95% confidence interval [CI], 1.68-11.5). The RR tended to be higher in association with higher initial doses (for initial doses

AB - Objective: To identify the incidence and risk factors for corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Design: Retrospective cohort study. Participants: Patients with ocular inflammation followed at 5 United States tertiary centers that initially were neither diabetic nor taking hypoglycemic medications. Methods: Eligible patients who used oral corticosteroids during follow-up were identified and followed longitudinally for initiation of hypoglycemic medication over 1 year after beginning corticosteroids. The remaining eligible patients were followed for 1 year after their initial visit. Survival analysis was used to calculate the risk of hyperglycemia requiring medical therapy and to identify potential risk factors. Main Outcome Measures: Initiation of hypoglycemic medications. Results: Among 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21%) initiated hypoglycemic therapy compared with 5 of 2666 patients (0.19%) not treated with oral corticosteroids (relative risk [RR], 4.39; 95% confidence interval [CI], 1.68-11.5). The RR tended to be higher in association with higher initial doses (for initial doses

UR - http://www.scopus.com/inward/record.url?scp=84864449060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864449060&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2012.01.043

DO - 10.1016/j.ophtha.2012.01.043

M3 - Article

C2 - 22484116

AN - SCOPUS:84864449060

VL - 119

SP - 1569

EP - 1574

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 8

ER -